Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Thanh-Trang Vo"'
Autor:
Thanh-Trang Vo, Lee-or Herzog, Roberta Buono, Jong-Hoon Scott Lee, Sharmila Mallya, Madeleine R. Duong, Joshua Thao, Moran Gotesman, David A. Fruman
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The mechanistic target of rapamycin (mTOR) is a kinase whose activation is associated with poor prognosis in pre-B cell acute lymphoblastic leukemia (B-ALL). These and other findings have prompted diverse strategies for targeting mTOR signal
Externí odkaz:
https://doaj.org/article/f6da06c10adf41ed853a873822db0706
Autor:
Van Bang Nguyen, Van Vy Hau Nguyen, Chi Van Le, Pham Nguyen Tuyen Linh, Xuan Nguyen Thi, Thanh Trang Vo
Publikováno v:
Clinical Case Reports, Vol 12, Iss 2, Pp n/a-n/a (2024)
Key Clinical Message Pretibial myxedema is a rare skin lesion in Grave's disease, which required topical glucocorticoid administration in long‐term treatment. The patient's lesion has shrunk and become flatter than before treatment. Abstract We pre
Externí odkaz:
https://doaj.org/article/357c24e8da574f6690299bd5c9891af0
Publikováno v:
British Journal of Clinical Pharmacology. 82:1213-1228
Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, division and survival. Many haematologic malignancies exhibit elevated or aberrant mTOR activation, supporting the launch of numerou
Autor:
Jacqueline Smith, Amos Fung, Bianca J. Lee, Ze'ev Ronai, Honyin Chiu, Thanh-Trang Vo, Lee-or Herzog, David A. Fruman, James B. Aggen, Nidhi Tibrewal, David Wildes, Davide Ruggero, Mallika Singh, Sharmila Mallya
Publikováno v:
Molecular Cancer Research. 18:IA17-IA17
mTORC1 signaling is elevated in most lymphoid malignancies and frequently is associated with poor prognosis. Targeting mTORC1 with rapalogs or mTOR kinase inhibitors (TOR-KIs) are two strategies that both have limitations. Rapalogs are weak inducers
Autor:
Amy Chadburn, Thanh-Trang Vo, Brian J Lanutti, Francesca Arruga, Nicoletta Vitale, Arianna Di Napoli, Langdon L. Miller, Mira Ko, Katti Jessen, Richard R. Furman, Tiziana Vaisitti, John N. Allan, Silvia Deaglio, Esteban Braggio
Publikováno v:
Blood. 134:2856-2856
ROR1 is a transmembrane receptor with tightly controlled expression during development. It is present on multiple tumor types but not on normal adult tissues. Hematological malignancies are often ROR1-positive, including chronic lymphocytic leukemia
Publikováno v:
Oncotarget
Scott Lee, J; Tang, SS; Ortiz, V; Vo, TT; & Fruman, DA. (2015). MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget, 6(34), 35202-35217. doi: 10.18632/oncotarget.6051. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/1jq6t5vp
Oncotarget, vol 6, iss 34
Scott Lee, J; Tang, SS; Ortiz, V; Vo, TT; & Fruman, DA. (2015). MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget, 6(34), 35202-35217. doi: 10.18632/oncotarget.6051. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/1jq6t5vp
Oncotarget, vol 6, iss 34
The PI3K/AKT/mTOR axis promotes survival and is a frequently mutated pathway in cancer. Yet, inhibitors targeting this pathway are insufficient to induce cancer cell death as single agents in some contexts, including diffuse large B cell lymphoma (DL
Autor:
David A. Fruman, Thanh-Trang Vo
Publikováno v:
Cancer discovery, vol 5, iss 7
The phosphatases PTEN and INPP4B have been proposed to act as tumor suppressors by antagonizing PI3K-AKT signaling and are frequently dysregulated in human cancer. Although PTEN has been extensively studied, little is known about the underlying mecha
Autor:
George F. Widhopf, Yousaf A. Mian, Laura Z. Rassenti, Thanh-Trang Vo, Katti Jessen, Thomas J. Kipps
Publikováno v:
Blood. 132:1862-1862
ROR1 is an onco-embryonic surface antigen expressed on chronic lymphocytic leukemia (CLL) and a variety of other cancers, but not on most normal adult tissues. We generated a humanized IgG1 monoclonal antibody (mAb) cirmtuzumab (formerly UC-961) that
Autor:
Kyle Howerton, Ssang-Taek Lim, Dan A. Hanson, Yangmi Lim, Susan J. Fisher, Nicholas Larocque, Xiao Lei Chen, David D. Schlaepfer, Dusko Ilic, Thanh-Trang Vo
Publikováno v:
Molecular Cell. 29:9-22
Summary FAK is known as an integrin- and growth factor-associated tyrosine kinase promoting cell motility. Here we show that, during mouse development, FAK inactivation results in p53- and p21-dependent mesodermal cell growth arrest. Reconstitution o
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.